Background: fSCIG can be administered at similar doses/volumes and dosing intervals as intravenous immunoglobulin G (IgG) (IVIG) but, similar to conventional subcutaneous IgG, is associated with a lower risk of systemic and higher risk of local adverse reactions (ARs). Objective: We report local AR rates over time in patients with PID aged ≥ 16 years treated with fSCIG for up to ~3.5 years in the fSCIG pivotal phase 3 study and its extension. Methods: Following a 3-month IVIG treatment period, patients initiated fSCIG on a dose ramp-up schedule and thereafter received fSCIG every 3 (Q3W) or 4 weeks (Q4W) for ~18 months, followed by up to an additional 21 months. Local AR (temporally associated and/or causally related adverse events) rates were evaluated over time. 
